Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER networkLoreta A. Kondili, Stefano Vella, Giovanni Battista Gaeta et al.|PLoS ONE|2017Cited by 114
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Gabriella d’Ettorre, Andrea Antinori et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33
Simplification to atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir+2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trialRoberta Gagliardini, Andrea De Luca, Massimiliano Fabbiani et al.|Unknown|2016Cited by 11